During the past decade, Guangxi Medical University Affiliated Tumor Hospital conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Guangxi Medical University Affiliated Tumor Hospital" #1 sponsor was "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 16 trials, followed by "BeiGene" with 6 trials sponsored, "Shanghai Henlius Biotech" with 2 trials sponsored, "Ascentage Pharma Group Inc." with 1 trials sponsored and "Beijing Shenogen Biomedical Co., Ltd" with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Guangxi Medical University Affiliated Tumor Hospital" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Affiliated Cancer Hospital & Institute of Guangzhou Medical University" with 1 trials as a collaborator, "Anhui Provincial Hospital" with 1 trials as a collaborator, "Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group" with 1 trials as a collaborator and "Beijing Hospital" with 1 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Guangxi Medical University Affiliated Tumor Hospital" are "Non Small Cell Lung Cancer" (3 trials), "Non-small Cell Lung Cancer" (2 trials), "Advanced Endometrial Cancer" (1 trials), "Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma" (1 trials) and "Advanced HBV-Related Hepatocellular Carcinoma (HCC)" (1 trials). Many other conditions were trialed in "Guangxi Medical University Affiliated Tumor Hospital" in a lesser frequency.

Most popular intervention types in "Guangxi Medical University Affiliated Tumor Hospital" are "Drug" (36 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Anlotinib" (9 trials), "Placebo" (7 trials), "Tislelizumab" (5 trials), "TQB2450" (4 trials) and "Cisplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Guangxi Medical University Affiliated Tumor Hospital" are 35 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Guangxi Medical University Affiliated Tumor Hospital". 2 are not yet recruiting, 11 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Guangxi Medical University Affiliated Tumor Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Guangxi Medical University Affiliated Tumor Hospital, 4 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".